• As planned, 333 patients were randomized by the end of December 2023 across 11 clinical centers in the United States
• This important milestone should make it possible to obtain the first results of the study in the second quarter of 2024, in accordance with the announced schedule
Bordeaux, January 9, 2024 – 6:00 p.m. CET – Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces that it has a key milestone by successfully finalizing the recruitment of 333 patients suffering from cannabis addiction as part of its phase 2b clinical study with AEF0117.
To receive all AELIS FARMA financial information in real time, request it by email to [email protected]. Your registration will be immediate.